SCTX Stock Forecast & Price Target

Scribe Therapeutics is attractive because STX-1150 has already shown a differentiated preclinical profile: >50% LDL-C lowering sustained for two years in NHPs, a >5x potency advantage in primary human hepatocytes, and no meaningful liver-safety signal at the lowest tested dose. The investment case is further supported by a large unmet need in PCSK9 therapy, where poor adherence leaves millions of ASCVD patients not at goal, while approved agents typically lower LDL-C by ~50-60% and annual class sales exceed $5B despite limited penetration. Financially, the company appears well funded with roughly $180M pro forma cash and runway into 1H29, which should support the 1H27 STX-1150 readout and initial XE development without near-term partnership dependence.

Scribe Therapeutics is viewed negatively because its lead asset, STX-1150, is only now in Phase 1, while the broader ELXR/XE platform still lacks human validation and the first-in-human data are not expected until 1H27. The company has no product revenue, expects continued losses, and is projected to use about $50.8 million of cash in FY2026 and $81.9 million in FY2027, even though cash of roughly $170 million is said to fund operations into 1H29, not through approval. Commercially, it faces an unproven epigenetic-silencing model, competitive pressure from approved PCSK9 therapies and rival genetic medicines, plus financing, safety, and reimbursement risks that could dilute shareholders or delay development.